Clinical applicability of xTAG liquidchip technology as EGFR mutations detection method in lung cancer
10.13315/j.cnki.cjcep.2014.11.010
- VernacularTitle:xTAG液相芯片技术用于肺癌 EGFR基因突变检测的临床适用性
- Author:
Yuanjie GUO
;
Wei WANG
;
Sha FU
;
Fang LIU
;
Jing GUO
;
Jianyong SHAO
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
EGFR gene mutation;
xTAG liquidchip technology;
sanger sequencing
- From:
Chinese Journal of Clinical and Experimental Pathology
2014;(11):1242-1246
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To analyze EGFR exon 18 ~21 gene mutations in lung cancer, and compare xTAG liquidchip technology and Sanger sequencing technology in clinical practice. Methods 1 139 tumor tissue samples from phaseⅠtoⅣlung cancer patients were randomly collected. DNA was extracted from the samples. EGFR gene mutation status in exon 18~21 was detected by xTAG liquidchip technology and Sanger sequencing technology respectively. Results The mutation status of EGFR was obtained by xTAG liquidchip technology in 1 134 patients, and 1 105 by Sanger sequencing technology, detection success rate was 99. 56% and 97. 01% respective-ly. The sensitivity and specificity of xTAG liquidchip technology Comparing with Sanger sequencing was 99. 59% and 94. 54%. Sever-al cases of multiple mutations were detected by both methods. All mutation types detected by two methods are fully consistent. Conclu-sions Comparing with Sanger sequencing technology, xTAG liquidchip technology, which is able to detect mutations of exon 18~21 simultaneously, is more convenient and efficient for EGFR gene mutation detection in lung cancer.
